Drug development, diagnostics and adoptive cell therapies without limitations—that’s the world we envisioned when we founded this company over 10 years ago. We cut our teeth in academia, in R&D and in the clinics where we learned first-hand the limitations of biologically-derived cellular reagents: resource-intensive products that fall short in performance and accuracy, unstable and inconsistent over time, and a complex, ethically-challenged supply chain—all leading to unequal access to the most basic diagnostic testing and life-saving therapies.
We knew there had to be a better way.
And there is.
We applied the tenets of biochemistry, high-precision manufacturing and polymer chemistry to create FlowCytes™. These shelf-stable, synthetic cells can be custom printed on demand, at scale, in real-time. Slingshot’s revolutionary technology decreases cost, shortens development timelines and increases stability, impact and accessibility. There is a new paradigm for drug development, diagnostics and cell therapy—one without limitations.
Improve the accuracy and performance of biomedical instruments and devices
Lower the cost and barriers of drug development and diagnostics
Make healthcare more accessible around the world
Advancing cell biology to develop innovative solutions for human health
Making medical testing simple and accessible
Making personalized therapeutics a reality